Skip to main content
OpenTrials
Completed

NCT Number: NCT01518036

Use of Somatropin in Turner Syndrome

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Genetic Disorder Cardiovascular Abnormalities Cardiovascular Diseases Chromosome Disorders Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Disorders of Sex Development Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Gonadal Disorders Gonadal Dysgenesis Heart Defects, Congenital Heart Diseases Male Urogenital Diseases Sex Chromosome Disorders Sex Chromosome Disorders of Sex Development Turner Syndrome Urogenital Abnormalities Urogenital Diseases

Age range

2 year–11 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Novo Nordisk Investigational Site

Crawley, RH11 9RT, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Turner Syndrome
  • Not previously treated with growth hormone or androgen
  • Well-documented height over the previous 12 months
  • Informed consent of parents (and child if appropriate)

Exclusion criteria

  • Growth hormone (GH) deficiency based on a GH stimulation test

Treatment and study plan

Somatropin

Drug

2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached

Primary outcomes

  1. Final height in cm

Secondary outcomes

  1. Ratio between change in bone age and change in chronological age

  2. Age at onset of puberty

  3. Adverse events

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

The Use of Norditropin® in Turner's Syndrome

Important dates

Study start
1987
Primary completion
2004
Study completion
2004
First posted
Jan 25, 2012
Registry last updated
Feb 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.